Cancer therapies that engage with the patient’s immune system are an increasingly important weapon in the oncologist’s arsenal and have shown great promise for extending life and even curing a variety of malignancies. Outside of the exciting but complex landscape of cell therapies, there are also a wide variety of immunotherapies that take the form of antibodies, small molecules, and other molecular entities that empower the immune system to more effectively attack cancer, with the potential for durable regression. This portfolio of Stanford technologies explores new targets, state-of-the-art delivery systems, and novel large and small molecule drugs that can extend the range of these cures to more patients, offering next-generation approaches to harness the immune system to fight cancer.